Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997

• Published in: Journal of clinical oncology Vol. 25; no. 7; pp. 799 - 804
• Main Authors: Grever, Michael R., Lucas, David M., Dewald, Gordon W., Neuberg, Donna S., Reed, John C., Kitada, Shinichi, Flinn, Ian W., Tallman, Martin S., Appelbaum, Frederick R., Larson, Richard A., Paietta, Elisabeth, Jelinek, Diane F., Gribben, John G., Byrd, John C.
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 01.03.2007; Lippincott Williams & Wilkins
• Subjects: ADP-ribosyl Cyclase 1 - analysis; Adult; Aged; Aged, 80 and over; Apoptosis; Biological and medical sciences; Chromosome Aberrations; Female; Genes, p53; Hematologic and hematopoietic diseases; Humans; Immunoglobulin Heavy Chains - genetics; Immunoglobulin Variable Region - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Mutation; Prospective Studies; Tumors; ZAP-70 Protein-Tyrosine Kinase - analysis; Phase III trial; Human; Chemotherapy; Chronic lymphocytic leukemia; Cancerology; Prognosis; Treatment; Genetics; Malignant hemopathy

Genomic features including unmutated immunoglobulin variable region heavy chain (IgVH) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family...